Aclaris Reports Positive Phase 1a ATI-052 Results and $151M Year-End Cash
Aclaris ended 2025 with $151.4 million in cash and marketable securities, down from $203.9 million, securing funding into second-half 2028. Interim Phase 1a ATI-052 data showed favorable safety, dose-proportional PK and robust target engagement, triggering Phase 1b AD and asthma trials with H2 2026 readouts.
1. Fourth Quarter Financial Update
Aclaris ended 2025 with $151.4 million in cash and marketable securities, down from $203.9 million a year earlier. The company projects this liquidity will fund operations into the second half of 2028 without additional financing.
2. ATI-052 Bispecific Antibody Progress
Interim Phase 1a single and multiple ascending dose data for the bispecific anti-TSLP/IL-4Rα ATI-052 showed favorable safety, dose-proportional pharmacokinetics and robust target engagement, supporting up to quarterly dosing. Phase 1b proof-of-concept trials in atopic dermatitis and asthma have been initiated, with top-line results expected in H2 2026.
3. Bosakitug Phase 2 and Phase 2b Planning
A randomized Phase 2 trial of anti-TSLP monoclonal antibody bosakitug in moderate-to-severe atopic dermatitis is ongoing, with top-line results anticipated in the second half of 2026. Planning for a Phase 2b program covering both asthmatic and dermatologic indications is underway, targeting initiation in H2 2026.
4. Oral ITK Inhibitors and Preclinical Insights
The lead ITK inhibitor ATI-9494 is on track for an IND filing in the second half of 2026 after demonstrating potent Th1/Th2 blockade and favorable half-life. Preclinical results for ATI-2138, an ITK/JAK3 dual inhibitor, showed 93% murine hair regrowth versus 78% with ritlecitinib in a severe alopecia model, highlighting best-in-class potential.